Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Human Genetics, |
RCV000680602 | SCV000808030 | uncertain significance | Connective tissue disorder | 2018-06-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004026161 | SCV003623672 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2022-05-09 | criteria provided, single submitter | clinical testing | The c.314C>T (p.S105F) alteration is located in exon 2 (coding exon 2) of the PRKG1 gene. This alteration results from a C to T substitution at nucleotide position 314, causing the serine (S) at amino acid position 105 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003741213 | SCV004553754 | uncertain significance | Aortic aneurysm, familial thoracic 8 | 2023-08-16 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 561327). This variant has not been reported in the literature in individuals affected with PRKG1-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.004%). This sequence change replaces serine, which is neutral and polar, with phenylalanine, which is neutral and non-polar, at codon 105 of the PRKG1 protein (p.Ser105Phe). |